Heartpoint Global Wins Top Honor in TCT 2023 Shark Tank Innovation Competition

Award Recognizes Breakthrough Innovation for INTELLISTENT^®, Paving the Way for Citizens Worldwide to Receive Affordable, Cutting-Edge Cardiac Care

NEW YORK , Oct. 25, 2023 /PRNewswire/ -- HeartPoint Global is pleased to announce that INTELLISTENT^® the company's novel multi-lumen stent system for interventional adjustment of pulmonary blood flow in congenital heart disease, was the winner in the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

"HeartPoint Global's pioneering approach to treating Pulmonary Arterial Hypertension caused by congenital heart disease and pulmonary arterial hypertension (PAH-CHD) stood out due to its potential to address a significant unmet clinical need," said Dr. Juan F. Granada, MD, CEO and President of the Cardiovascular Research Foundation (CRF). "It was selected as the winner by a distinguished panel of judges, including physician innovators, physician investors, and experts actively involved in building companies and developing innovative, high-impact therapies."

HeartPoint Global's INTELLISTENT^® is a groundbreaking multi-lumen stent system for interventional adjustment of pulmonary blood flow to treat PAH-CHD. It reproduces the effects of the validated surgical therapy, pulmonary artery banding, and is patented in over 20 countries, including the U.S., European Union, and China. The device is placed in the main pulmonary artery and the arterial branches and allows for the adjustment of blood flow in the heart lung system. Patients with severe PAH can become surgical candidates after INTELLISTENT^® treatment (bridge-to-surgery). The technology embedded in INTELLISTENT^® will be used to treat many other indications.

Previous successful pre-clinical tests of the implant system studied the direct placement of the device in the main pulmonary artery and bilateral delivery in the left and right pulmonary arteries and branches. Research presented at TCT by Dr. Elena K. Amin, MBChB, Pediatric Cardiologist at the University of California, San Francisco, and a member of HeartPoint Global's advisory board, demonstrated first proof-of-concept results showing that reversible pulmonary artery banding in left ventricle failure with preserved right ventricle function provides a novel alternative as a 'bridge-to transplant' or as an alternative to destination therapy in infants and children with advanced left ventricle dilated cardiomyopathy. 

Seth Bogner, Chairman and CEO of HeartPoint Global said, "We are deeply honored to be bestowed with this prestigious award. TCT stands as a pinnacle platform for highlighting innovation in cardiovascular medicine. Having our technology acknowledged by such a distinguished panel of judges is truly humbling. We are eager to forge ahead with HeartPoint Global's in-human trials and anticipate its substantial clinical impact in the future."

The TCT Shark Tank Innovation Competition has partnered with the Jon DeHaan Foundation for six years to provide a $200,000 award for the winner. The Shark Tank Innovation Competition aims to identify and showcase the most groundbreaking concepts in modern cardiovascular medicine. This year, six companies were chosen to present at TCT. The Jon DeHaan Foundation is dedicated to supporting those working to advance cardiac medicine and provides grants and awards to individuals and companies who focus on innovative developments in cardiovascular medicine, including research, prevention, diagnosis, treatment, or rehabilitation.

About HeartPoint Global

As a pioneer of breakthrough medical solutions, HeartPoint Global (HPG) is paving the way for citizens worldwide to receive affordable, cutting-edge cardiac care. In response to the 92 percent of the world's population that has no access to cardiac surgery, the leading medical device company is on a mission to provide innovative, minimally invasive, and accessible cardiac care on a global scale to ensure those who would otherwise suffer from or die of cardiovascular disease receive the care they need. For more information, visit www.heartpointglobal.com.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is one of the world's leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 30 years, CRF has helped accelerate medical breakthroughs and educated doctors on the latest treatments for heart disease. CRF's centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Every year TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit www.crf.org and www.tctconference.com.

Media Contact
Brigit Hennaman
VP, Rubenstein Public Relations
[email protected]
212-805-3005

SOURCE HeartPoint Global